(lp0
S"Ionis Pharmaceuticals Inc Turns a Profit With Other Drugmakers' Money Motley Fool - Mar 1, 2017 Ionis Pharmaceuticals  reported fourth-quarter earnings on Tuesday. The biotech has two drugs on the market, but given Kynamro's low sales and the fact that spinal muscular atrophy drug Spinraza only launched in late December, most of&nbsp;..."
p1
aS"Company Update : Here's Why Ionis Pharmaceuticals Inc Shares ... Smarter Analyst - Feb 28, 2017 Ionis Pharmaceuticals Inc  reported that it outperformed its financial guidance by ending 2016 with pro forma operating income of $25.8 million and $665.2 million in cash, cash equivalents and short-term investments.Ionis Pharmaceuticals  Beats on Q4 Earnings - Yahoo FinanceIonis Pharmaceuticals Inc.  Moves Higher on Volume Spike for March 03 - Equities.com"
p2
aS'Akcea and Ionis Announce Positive Results from Pivotal Study of Volanesorsen ... PR Newswire  - Mar 6, 2017 CARLSBAD, Calif. and CAMBRIDGE, Mass., March 6, 2017 /PRNewswire/ -- Akcea Therapeutics, a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. , today announced that the pivotal Phase 3 APPROACH study of volanesorsen met its&nbsp;...Why Ionis Pharmaceuticals Rallied 12% in February - Motley FoolIonis Pharmaceuticals, Inc. : Checking the Chart - The USA Commerce'
p3
aS'Why Ionis Pharmaceuticals Is Tumbling 10% Today Motley Fool - Mar 10, 2017 What happened. After highly regarded investment firm Goldman Sachs cut its rating on the company, Ionis Pharmaceuticals  shares dropped by more than 10% at 1:45 p.m. EST today.Analyst Downgrades  Ionis Pharmaceuticals  Stock Gets Downgraded ... - Market ExclusiveIonis Pharmaceuticals Inc.  Moves Lower on Volume Spike for March 10 - Equities.com'
p4
aS"Goldman Sachs downgrade today creates a buying opportunity. Seeking Alpha - Mar 13, 2017 Long-term investors should stiff-arm today's Goldman Sachs downgrade of Ionis Pharmaceuticals  from Neutral to Sell because analyst Salveen Richter has ignored recent evidence exonerating the platform of alleged toxicity."
p5
aS'Ionis Pharmaceuticals Inc.  Moves Lower on Volume Spike for March 17 Equities.com - Mar 17, 2017 Ionis Pharmaceuticals Inc.  traded on unusually high volume on Mar. 17, as the stock lost 3.6% to close at $40.22. On the day, Ionis Pharmaceuticals Inc. saw 3.11 million shares trade hands on 15,821 trades. Considering that the stock averages ...Just the Facts on Ionis Pharmaceuticals, Inc.  - StockNewsJournalStock Showing Surging Activity: Ionis Pharmaceuticals, Inc.  - HugoPress'
p6
aS"Featured Stock Update: Ionis Pharmaceuticals, Inc.  HugoPress - 14 hours ago Goldman Sachs Downgrades Ionis Pharmaceuticals, Inc. 's stock to Sell with the price target of $25. This rating was issued on 3/10/17.The Ionis Pharmaceuticals Inc  Receives $42.93 Average PT from Brokerages - Petro Global News 24Norges Bank Takes Position in Ionis Pharmaceuticals Inc  - Sports Perspectives"
p7
aS'Ionis Pharma Lipid Disorder Candidate Positive in Phase III Yahoo Finance - Mar 8, 2017 Akcea Therapeutics, an affiliate of Ionis Pharmaceuticals, Inc. IONS, recently announced positive results from a pivotal phase III study evaluating its pipeline candidate volanesorsen for treatment of patients with familial chylomicronemia syndrome .'
p8
aS"Ionis' Latest Attempt To Weaponize Antisense Against Cancer Seeking Alpha - Mar 15, 2017 Cancer-causing mutations in the KRAS gene have been studied for 30 years yet no direct inhibitor of mutant KRAS enzyme has entered clinical trials.What are Analyst's Indicators for The Chemours Company , Ionis ... - The USA CommerceIonis Pharmaceuticals, Inc.  recently sold by insider BENNETT C FRANK - Post Analyst"
p9
aS'SHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of Ionis ... Yahoo Finance - Mar 8, 2017 Ionis reported 8 serious adverse events concerned with volanesorsen. If you have any questions concerning your legal rights, please immediately contact Goldberg Law PC at 800-977-7401, or visit our website at http://www.'
p10
a.